Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to equity ratio is N/A as of Tuesday, October 6, 2026.
DEBT TO EQUITY RATIO
N/A
Latigo Biotherapeutics Inc.
Market Cap
$1.00B
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$988.96M
Debt to Equity Ratio
0.23
TTM Avg
0.21
3Y Avg
0.27
5Y Avg
0.36
Market Cap
$1.02B
Debt to Equity Ratio
1.59
TTM Avg
4.87
3Y Avg
5.44
5Y Avg
5.44
Market Cap
$982.07M
Debt to Equity Ratio
0.61
TTM Avg
0.74
3Y Avg
0.79
5Y Avg
0.93
Market Cap
$1.03B
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.05
5Y Avg
0.03
Market Cap
$979.48M
Debt to Equity Ratio
0.52
TTM Avg
0.95
3Y Avg
0.70
5Y Avg
0.50
Market Cap
$974.91M
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$1.03B
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $1.00B | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $988.96M | 0.23 | 0.21 | 0.27 | 0.36 |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 1.59 | 4.87 | 5.44 | 5.44 |
| Pacira BioSciences, Inc. (PCRX)vs › | $982.07M | 0.61 | 0.74 | 0.79 | 0.93 |
| Janux Therapeutics, Inc. (JANX)vs › | $1.03B | 0.02 | 0.02 | 0.05 | 0.03 |
| MeiraGTx Holdings plc (MGTX)vs › | $979.48M | 0.52 | 0.95 | 0.70 | 0.50 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $974.91M | 0.02 | 0.01 | 0.01 | 0.01 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.03B | 0.01 | 0.01 | 0.01 | 0.01 |
| Immatics N.V. (IMTX)vs › | $1.03B | 0.04 | 0.03 | 0.05 | 0.11 |
| Aktis Oncology, Inc. (AKTS)vs › | $965.02M | 0.02 | N/A | N/A | N/A |
Debt/Equity
N/A
Current Ratio
N/A
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
